Chapter 4 - The Ghost of Room 412
The private intensive care pavilion at Providence St. Vincent smelled of medical ozone, dry air, and the hum of high-end life support machinery.
My chief of corporate security, Marcus Vance, had secured the entire fourth-floor west corridor within thirty minutes of my phone call. Four armed, plainclothes executive protection guards stood at the elevator bank, their badges discreetly concealed beneath dark charcoal suits.
Down the hall in a private consultation suite, Eli and Maya were sitting together on a leather sofa. Maya had eaten an entire bowl of warm chicken noodle soup and three sourdough rolls, her small hands wrapped around a mug of hot cocoa, wearing one of Eli’s warm fleece pullovers. Eli was showing her his specialized carbon-fiber running blades, explaining the spring mechanics with the passionate, serious pride only a seven-year-old boy could muster.
I stood outside Room 412, looking through the heavy glass observation window.
Inside, suspended in a tangle of infusion lines, ventilator tubing, and cardiac monitors, lay Elena Brooks.
She was thirty-two years old, but her body had been reduced to an ethereal, fragile shell. Her skin had the translucent pallor of fine porcelain, her dark hair fanned out across the white pillow like silk ribbons. An arterial line in her wrist pulsed with an erratic, sluggish rhythm on the telemetry screen above her bed.
Dr. Jonathan Reed, the chief of neuro-critical care and a longtime personal physician to my family, stepped up beside me, holding a thick, encrypted medical tablet.
“Her Glasgow Coma Scale is a four, Ronan,” Dr. Reed said quietly, his voice heavy with professional exhaustion. “She suffered an acute, catastrophic neuro-inflammatory crisis secondary to an aggressive, atypical presentation of autoimmune encephalitis. Her brain stem is under massive intracranial pressure.”
“Can you reduce the swelling?” I asked.
“With standard immunosuppressants and high-dose steroids? We’re throwing pebbles at a brick wall,” Reed replied, shaking his head. “Her blood-brain barrier has broken down. Within seventy-two hours, the swelling will cause herniation. The state hospital was forty-eight hours away from declaring her medically futile and petitioning for compassionate palliative withdrawal.”
“What’s the alternative, Jonathan?”
Reed hesitated, glancing over his shoulder toward the security detail before lowering his voice.
“There is an experimental monoclonal peptide called Synapse-9,” Reed whispered. “It was developed three years ago to cross the blood-brain barrier and reverse acute cytokine storms in pediatric and young adult neurological trauma. In preclinical trials, it had a ninety-two percent cellular recovery rate within thirty-six hours.”
“Then give it to her,” I said without hesitation. “I’ll write the check right now. Ten million, twenty million—whatever the research facility demands.”
“Money can't buy it, Ronan,” Reed said, looking directly into my eyes. “The global patent, the synthetic molecular stock, and the experimental FDA compassionate-use licenses are owned by an exclusive logistics and biomedical monopoly.”
“Who?”
“Corvus Bio-Logistics.”
The air left my chest in a sharp, cold gasp.
“Corvus?” I repeated, the corporate name echoing off the glass partition like a curse.
“Yes,” Reed said. “And it gets worse. Look at her employment file.”
Dr. Reed tapped his tablet, pulling up a sealed dossier from the Oregon State Medical Registry.
A photograph appeared on the screen: Elena Brooks from five years earlier, wearing a white laboratory coat, her eyes bright, proud, and brilliant, standing before the biomedical research complex in Seattle.
DR. ELENA BROOKS, Ph.D. – FORMER CHIEF RESEARCH BIOCHEMIST, CORVUS PHARMACEUTICALS.STATUS: TERMINATED FOR GROSS INSUBORDINATION / LICENSING PERMANENTLY REVOKED.
“Elena Brooks wasn't just a victim of this disease, Ronan,” Dr. Reed revealed, his jaw tightening. “She was the lead biochemist who invented Synapse-9. Five years ago, she discovered that Corvus’s executive board—led by Julian Sterling’s private equity partners—was deliberately cutting the stabilizer molecules in the pediatric batches to triple their manufacturing margins, causing fatal neurological seizures in clinical trial subjects.”
Reed scrolled through the sealed whistleblower filings.
“She tried to report them to the FDA,” Reed whispered. “Corvus used their legal army to destroy her. They fabricated corporate espionage charges against her, stripped her doctorate, seized her research patents, and blacklisted her from every hospital and university in North America. She was forced to work night shifts as a low-wage laboratory assistant just to buy groceries for Maya.”
My knuckles cracked against the wooden handrail of the observation window.
The puzzle pieces slammed together with terrifying, catastrophic clarity.
The billion-dollar merger I was supposed to sign on Friday wasn't an ordinary logistics expansion. Julian Sterling and Corvus were using Vale Meridian’s clean, pristine shipping networks to move counterfeit, unstable biomedical products across seven states.
And the eight-year-old girl who had thrown her body into the mud to keep my crippled son from falling was the daughter of the woman they had butchered to keep their empire quiet.
The corridor doors banged open.
Julian Sterling strode down the hallway, flanked by two corporate attorneys in thousand-dollar suits, his face twisted in cold, aristocratic fury.
“Ronan!” Julian’s voice echoed off the sterile walls. “What the hell is the meaning of this? Why are my private security teams reporting that you diverted four million dollars from our joint escrow fund to a charity case in St. Vincent’s?”
Julian stopped three paces from me, his eyes flicking through the glass window to Elena’s dying form.
May you like
Then he looked at me, and a slow, sickening sneer pulled at his lips.
“Well, well,” Julian murmured, his voice dripping with venomous amusement. “Look who found our little ghost.”
